Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody and BACE in NSCLC
NCT05605613Phase 3Recruiting
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC). Started Oct 2022; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05605613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605613.